Biogen Q2 2026 Earnings
Rev $2.74B (est $2.47B) -Leqembi Rev $184M (est $186.4M) -Multiple Sclerosis Rev $963M (est $902.2M) -Adj EPS $3.60 (est $2.89) -Product Rev. $1.92B (est $1.77B) -Now Sees Yr Rev Increase By Mid-Single Digit Percentage -Sees FY Adj EPS $12 To $13, Saw $14.25 To $15.25 -Yr View Updated To Reflect Acquisition-Related Costs
Story updates
10:23:39 AM UTC
SquawkNews
Biogen Q2 2026 Earnings
Rev $2.74B (est $2.47B) -Leqembi Rev $184M (est $186.4M) -Multiple Sclerosis Rev $963M (est $902.2M) -Adj EPS $3.60 (est $2.89) -Product Rev. $1.92B (est $1.77B) -Now Sees Yr Rev Increase By Mid-Single Digit Percentage -Sees FY Adj EPS $12 To $13, Saw $14.25 To $15.25 -Yr View Updated To Reflect Acquisition-Related Costs